| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 0.75% |
| NAV | ₹129.54 (13 Jul 2020) |
|---|---|
| Fund Started | 01 Jan 2013 |
| Fund Size | ₹5,699 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Bayer CropScience Ltd. | Healthcare | Equity | 4.4% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 3.5% |
| Shree Cement Ltd. | Construction | Equity | 3.2% |
| Abbott India Ltd. | Healthcare | Equity | 2.6% |
| Coromandel International Ltd. | Chemicals | Equity | 2.5% |
| Tata Consumer Products Ltd. | FMCG | Equity | 2.5% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 2.4% |
| Mphasis Ltd. | Technology | Equity | 2.3% |
| Berger Paints India Ltd. | Chemicals | Equity | 2.1% |
| Atul Ltd. | Chemicals | Equity | 2.0% |
L&T Midcap Fund Direct Growth is a Equity Mutual Fund Scheme launched by L&T Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Soumendra Nath Lahiri, Vihang Naik is the Current Fund Manager of L&T Midcap Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹5,699 Cr and the Latest NAV as of 13 Jul 2020 is ₹129.54.
The L&T Midcap Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year.
Aims to generate long term capital appreciation by investing primarily in mid-cap stocks that have market capitalization between Rs. 300 Crore to Rs. 3000 Crore.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.